In a recent study conducted by the Center for the Biology of Chronic Disease (CBCD), researchers have uncovered the potential risks associated with hidden viruses, such as cytomegalovirus (CMV), and their link to premature death. The findings, published in the medical journal Antiviral Therapy, employ the microcompetition model to investigate why latent viruses like CMV, EBV, HPV, and HSV, which may not display clear symptoms, could be widespread and lead to health problems. The study explores why some people develop diseases from latent viruses and others don’t. It suggests that the viral copy number in the body, or the number of viral genomes, is a key factor, with higher numbers increasing the risk of developing a major disease sooner. Dr. Hanan Polansky’s research highlights the impact of latent viruses on health and lifespan. Treatments like Gene-Eden-VIR and Novirin show promise in controlling these viruses, potentially preventing diseases and extending life. Clinical tests by CBCD prove their effectiveness against HPV, HSV, CMV, and EBV, as documented in reputable journals. Addressing latent viruses is crucial for improving health outcomes and uncovering a previously overlooked aspect of our well-being.